Biomarkers for Response to Immune Checkpoint Blockade

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071

Profiling Tumor Infiltrating Immune Cells with CIBERSORT

Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M., & Alizadeh, A. A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7493-1_12 · Cited by 3,929

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888

Molecular and genetic properties of tumors associated with local immune cytolytic activity

Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,621

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237

Tumor mutational burden and response rate to PD-1 inhibition

Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022

Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment

Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Kim, S. T., Cristescu, R., Bass, A. J., Kim, K., Odegaard, J. I., Kim, K., Liu, X. Q., Sher, X., Jung, H., Lee, M.-J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0101-z · Cited by 1,680

Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells

Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641

CDK4/6 inhibition triggers anti-tumour immunity

Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Balar, A. V., Castellano, D., O’Donnell, P. H., Grivas, P. D., Vuky, J., Powles, T. B., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,351

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger‐Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D. A., Vennapusa, B., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,287

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260

PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma

Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Chung, H. C., Ros, W., Delord, J., Perets, R., Italiano, A., Shapira‐Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,075

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013

Classification and characterization of microsatellite instability across 18 cancer types

Hause, R. J., Pritchard, C. C., Shendure, J., & Salipante, S. J. (2016) · Nature Medicine · doi:10.1038/nm.4191 · Cited by 982

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Bakir, M. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 967

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 900

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies

Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770 · cited 2×

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Bensch, F., van der Veen, E. L., Hooge, M. N. L., Jorritsma‐Smit, A., Boellaard, R., Kok, I. C., Oosting, S. F., Schroder, C. P., Hiltermann, T. J. N., van der Wekken, A. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0255-8 · Cited by 749

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735

DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity

Härtlova, A., Erttmann, S. F., Raffi, F. A., Schmalz, A. M., Resch, U., Anugula, S., Lienenklaus, S., Nilsson, L. M., Kröger, A., Nilsson, J. A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.012 · Cited by 716

Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations

Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Sharma, P., Callahan, M. K., Bono, P., Kim, J. W., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 681

DNA Damage and Repair Biomarkers of Immunotherapy Response

Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D’Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 664

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

Łuksza, M., Riaz, N., Makarov, V., Balachandran, V. P., Hellmann, M. D., Solovyov, A., Rizvi, N. A., Merghoub, T., Levine, A. J., Chan, T. A.-T., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 655

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S. J., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 630

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3342 · Cited by 579

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis

Shen, X., & Zhao, B. (2018) · BMJ · doi:10.1136/bmj.k3529 · Cited by 567

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Niemeijer, A.-L. N., Leung, D. K.-W., Huisman, M. C., Bahce, I., Hoekstra, O. S., van Dongen, G. A. M. S., Boellaard, R., Du, S., Hayes, W., Smith, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07131-y · Cited by 489

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

Hsu, C., Lee, S., Ejadi, S., Even, C., Cohen, R. B., Tourneau, C. L., Mehnert, J. M., Algazi, A. P., van Brummelen, E. M. J., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.3675 · Cited by 471

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.053 · Cited by 469

Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma

Prat, A., Navarro, A., Paré, L., Reguart, N., Galván, P., Pascual, T., Martínez, A., Nuciforo, P., Comerma, L., Alos, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3556 · Cited by 455

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Ma, B. B. Y., Lim, W., Goh, B. C., Hui, E. P., Lo, K. W., Pettinger, A. M., Foster, N. R., Riess, J. W., Agulnik, M., Chang, A. Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0388 · Cited by 453

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment

Edwards, J. J., Wilmott, J. S., Madore, J., Gide, T. N., Quek, C. Y. J., Tasker, A. T., Ferguson, A. L., Chen, J., Hewavisenti, R., Hersey, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2257 · Cited by 448

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Chan, T. A.-T., Wolchok, J. D., & Snyder, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1508163 · Cited by 420

Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy

Goh, G., Walradt, T. J., Markarov, V., Blom, A., Riaz, N., Doumani, R., Stafstrom, K., Moshiri, A. S., Yelistratova, L., Levinsohn, J. L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6494 · Cited by 396

Immunogenic neoantigens derived from gene fusions stimulate T cell responses

Yang, W., Lee, K.-W., Srivastava, R. M., Kuo, F., Krishna, C., Chowell, D., Makarov, V., Hoen, D. R., Dalin, M. G., Wexler, L. H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0434-2 · Cited by 381

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

Mehnert, J. M., Panda, A., Zhong, J., Hirshfield, K. M., Damare, S., Lane, K., Sokol, L. O., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84940 · Cited by 376

A panoply of errors: polymerase proofreading domain mutations in cancer

Rayner, E., van Gool, I. C., Palles, C., Kearsey, S. E., Bosse, T., Tomlinson, I. P. M., & Church, D. N. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2015.12 · Cited by 374

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

van Gool, I. C., Eggink, F. A., Freeman-Mills, L., Stelloo, E., Marchi, E., de Bruyn, M., Palles, C., Nout, R. A., de Kroon, C. D., Osse, E. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0057 · Cited by 323

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

Wang, L., Saci, A., Szabo, P. M., Chasalow, S. D., Castillo-Martin, M., Domingo-Domenech, J., Siefker-Radtke, A., Sharma, P., Sfakianos, J. P., Gong, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05992-x · Cited by 313

Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages

Su, S., Zhao, J., Xing, Y., Zhang, X., Liu, J., Ouyang, Q., Chen, J., Su, F., Liu, Q., & Song, E. (2018) · Cell · doi:10.1016/j.cell.2018.09.007 · Cited by 309

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

Diem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M., & Larkin, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.467 · Cited by 308

Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma

Smith, C. C., Beckermann, K. E., Bortone, D. S., De Cubas, A. A., Bixby, L. M., Lee, S. J., Panda, A., Ganesan, S., Bhanot, G., Wallen, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121476 · Cited by 303

Gut microbiota modulate T cell trafficking into human colorectal cancer

Cremonesi, E., Governa, V., Garzon, J. F. G., Mele, V., Amicarella, F., Muraro, M. G., Trella, E., Galati-Fournier, V., Oertli, D., Däster, S. R., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313498 · Cited by 275

Computerized Image-Based Detection and Grading of Lymphocytic Infiltration in HER2+ Breast Cancer Histopathology

Basavanhally, A. N., Ganesan, S., Agner, S. C., Monaco, J., Feldman, M. D., Tomaszewski, J. E., Bhanot, G., & Madabhushi, A. (2009) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2009.2035305 · Cited by 272

Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer

Balli, D., Rech, A. J., Stanger, B. Z., & Vonderheide, R. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2128 · Cited by 240

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels

Stadler, Z. K., Battaglin, F., Middha, S., Hechtman, J. F., Tran, C., Cercek, A., Yaeger, R. D., Segal, N. H., Varghese, A. M., Reidy‐Lagunes, D. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.1067 · Cited by 238

Rapid Progression of Adult T-Cell Leukemia–Lymphoma after PD-1 Inhibitor Therapy

Ratner, L., Waldmann, T. A., Janakiram, M., & Brammer, J. E. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1803181 · Cited by 229

Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors

Nirmal, A. J., Regan, T. W., Shih, B. B.-J., Hume, D. A., Sims, A. H., & Freeman, T. C. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0342 · Cited by 215

Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer

Panda, A., Mehnert, J. M., Hirshfield, K. M., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L. O., Stein, M. N., Poplin, E. A., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx213 · Cited by 209

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Li, X., Cheng, Y., Zhang, M., Yan, J., Li, L., Fu, X., Zhang, X., Chang, Y., Sun, Z., Yu, H., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0559-7 · Cited by 203

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Subrahmanyam, P. B., Dong, Z., Gusenleitner, D., Giobbie-Hurder, A., Severgnini, M., Zhou, J., Manos, M., Eastman, L. M., Maecker, H. T., & Hodi, F. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0328-8 · Cited by 190

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma

Wong, P. F., Wei, W., Smithy, J. W., Ács, B., Toki, M. I., Blenman, K., Zelterman, D. A., Kluger, H. M., & Rimm, D. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2652 · Cited by 185

Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma

Panda, A., de Cubas, A. A., Stein, M., Riedlinger, G., Kra, J., Mayer, T., Smith, C. C., Vincent, B. G., Serody, J. S., Beckermann, K. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121522 · Cited by 181

Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086

Loi, S., Adams, S., Schmid, P., Cortés, J., Cescon, D. W., Winer, E. P., Toppmeyer, D., Rugo, H. S., Laurentiis, M. D., Nanda, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.005 · Cited by 180

PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer

Hunter, K. A., Socinski, M. A., & Villaruz, L. C. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0308-6 · Cited by 178

Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy

Zhang, Y. X., & Chen, L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2450 · Cited by 168

Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy

Riaz, N., Havel, J. J., Kendall, S. M., Makarov, V., Walsh, L. A., Desrichard, A., Weinhold, N., & Chan, T. A.-T. (2016) · Nature Genetics · doi:10.1038/ng.3677 · Cited by 151

Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer

Narayanan, S., Kawaguchi, T., Yan, L., Peng, X., Qi, Q., & Takabe, K. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6506-6 · Cited by 151

Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity

Engels, B., Engelhard, V. H., Sidney, J., Sette, A., Binder, D. C., Liu, R. B., Kranz, D. M., Meredith, S. C., Rowley, D. A., & Schreiber, H. W. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.018 · Cited by 149

Peptide-based PET quantifies target engagement of PD-L1 therapeutics

Kumar, D., Lisok, A., Dahmane, E., McCoy, M., Shelake, S., Chatterjee, S., Allaj, V., Sysa‐Shah, P., Wharram, B. L., Lesniak, W. G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122216 · Cited by 138

Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade

Galanina, N., Goodman, A. M., Cohen, P. R., Frampton, G. M., & Kurzrock, R. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0121 · Cited by 126

Replicative DNA polymerase mutations in cancer

Heitzer, E., & Tomlinson, I. P. M. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.12.005 · Cited by 121

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies

Gong, J., Chehrazi‐Raffle, A., Placencio-Hickok, V., Guan, M., Hendifar, A. E., & Salgia, R. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0225-x · Cited by 112

Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes

Solovyov, A., Vabret, N., Arora, K. S., Snyder, A., Funt, S. A., Bajorin, D. F., Rosenberg, J. E., Bhardwaj, N., Ting, D. T., & Greenbaum, B. D. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.042 · Cited by 106

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer

Solinas, C., Garaud, S., Silva, P. D., Boisson, A., den Eynden, G. V., de Wind, A., RISSO, P., Vitória, J. R., Richard, F., Migliori, E., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01412 · Cited by 106

Differences in Microsatellite Instability Profiles between Endometrioid and Colorectal Cancers

Wang, Y., Shi, C., Eisenberg, R., & Vnencak‐Jones, C. L. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.07.008 · Cited by 97

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Conroy, J. M., Pabla, S., Nesline, M., Glenn, S. T., Papanicolau‐Sengos, A., Burgher, B., Andreas, J., Giamo, V., Wang, Y., Lenzo, F. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0489-5 · Cited by 90

High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations

Boichard, A., Tsigelny, I. F., & Kurzrock, R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1284719 · Cited by 75

The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers

Takada, K., Toyokawa, G., Shoji, F., Okamoto, T., & Maehara, Y. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.10.014 · Cited by 75

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma

Schadendorf, D., Nghiem, P., Bhatia, S., Hauschild, A., Saïag, P., Mahnke, L. A., Hariharan, S., & Kaufman, H. L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338237 · Cited by 66

POLE proofreading defects: Contributions to mutagenesis and cancer

Park, V. S., & Pursell, Z. F. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.02.007 · Cited by 63

Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels

Heeren, A. M., Rotman, J., Stam, A. G. M., Pocorni, N., Gassama, A. A., Samuels, S., Bleeker, M. C. G., Mom, C. H., Zijlmans, H. J. M. A. A., Kenter, G. G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0526-z · Cited by 60

Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature

Deinlein, T., Lax, S., Schwarz, T., Giuffrida, R., Schmid‐Zalaudek, K., & Zalaudek, I. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.022 · Cited by 49

A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapy

Varn, F. S., Wang, Y., & Cheng, C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1513440 · Cited by 33

Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition

Johnson, D. B., & Dahlman, K. B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1795 · Cited by 26

The Next Decade of Immune Checkpoint Therapy

Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

Yang, C. Q., Xia, B.-R., Zhang, Z.-C., Zhang, Y., Lou, G., & Jin, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577869 · Cited by 358

Emerging strategies for treating metastasis

Esposito, M., Ganesan, S., & Kang, Y. (2021) · Nature Cancer · doi:10.1038/s43018-021-00181-0 · Cited by 175

Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity

White, E., Lattime, E. C., & Guo, J. Y. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.003 · Cited by 145

Heterogeneity in Cancer

MacDonald, W., Purcell, C., Pinho-Schwermann, M. P., Stubbs, N. M., Srinivasan, P. R., & El‐Deiry, W. S. (2025) · Cancers · doi:10.3390/cancers17030441 · Cited by 119

Immune Checkpoint Blockade Response Biomarkers

Garrido-Barros, M., Cháves, P., & Barragán, I. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_160

Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors

Zhu, Y., Zhao, F., Li, Z., & Yu, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s167400 · Cited by 29

Advances and prospects of biomarkers for immune checkpoint inhibitors

Yamaguchi, H., Hsu, J.-M., Sun, L., Wang, S., & Hung, M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101621 · Cited by 152

Biomarkers of response to immune checkpoint blockade in cancer treatment

Fujii, T., Naing, A., Rolfo, C. D., & Hajjar, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.010 · Cited by 77

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023